These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25302581)

  • 1. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
    Lee YK; Lee HW; Choi KH; Kim BS
    PLoS One; 2014; 9(10):e108737. PubMed ID: 25302581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
    Makino S; Egi M; Kita H; Miyatake Y; Kubota K; Mizobuchi S
    Int J Artif Organs; 2016 Jan; 39(1):16-21. PubMed ID: 26868216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
    Choi JY; Kang YJ; Jang HM; Jung HY; Cho JH; Park SH; Kim YL; Kim CD
    Medicine (Baltimore); 2015 Dec; 94(52):e2392. PubMed ID: 26717390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
    Maruyama Y; Yoshida H; Uchino S; Yokoyama K; Yamamoto H; Takinami M; Hosoya T
    Int J Artif Organs; 2011 Jul; 34(7):571-6. PubMed ID: 21786254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
    Baek NN; Jang HR; Huh W; Kim YG; Kim DJ; Oh HY; Lee JE
    Ren Fail; 2012; 34(3):279-85. PubMed ID: 22251267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
    Miyatake Y; Makino S; Kubota K; Egi M; Mizobuchi S
    Kobe J Med Sci; 2017 Aug; 63(1):E30-E36. PubMed ID: 29434171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
    Uchino S; Bellomo R; Morimatsu H; Morgera S; Schetz M; Tan I; Bouman C; Macedo E; Gibney N; Tolwani A; Oudemans-van Straaten H; Ronco C; Kellum JA
    Intensive Care Med; 2007 Sep; 33(9):1563-70. PubMed ID: 17594074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation in acute blood purification for acute renal failure in critical care.
    Shinoda T
    Contrib Nephrol; 2010; 166():119-125. PubMed ID: 20472999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study.
    Liu D; Zhao J; Xia H; Dong S; Yan S; Zhuang Y; Chen Y; Peng H
    Eur J Med Res; 2024 Jan; 29(1):72. PubMed ID: 38245802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
    Miyaji MJ; Ide K; Takashima K; Maeno M; Krallman KA; Lazear D; Goldstein SL
    Pediatr Nephrol; 2022 Nov; 37(11):2733-2742. PubMed ID: 35348901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.
    Wu MY; Hsu YH; Bai CH; Lin YF; Wu CH; Tam KW
    Am J Kidney Dis; 2012 Jun; 59(6):810-8. PubMed ID: 22226564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and efficacy of regional citrate anticoagulation in continuous renal replacement therapy in the presence of acute kidney injury after hepatectomy].
    Zhang C; Lin T; Zhang J; Liang H; Di Y; Li N; Gao J; Wang W; Liu S; Wang Z; Jiang H; Liu C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Aug; 30(8):777-782. PubMed ID: 30220281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
    Morabito S; Guzzo I; Solazzo A; Muzi L; Luciani R; Pierucci A
    J Nephrol; 2003; 16(4):566-71. PubMed ID: 14696760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
    Park JH; Her C; Min HK; Kim DK; Park SH; Jang HJ
    Int J Artif Organs; 2015 Nov; 38(11):595-9. PubMed ID: 26728787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.
    Stucker F; Ponte B; Tataw J; Martin PY; Wozniak H; Pugin J; Saudan P
    Crit Care; 2015 Mar; 19(1):91. PubMed ID: 25881975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding].
    Yin Y; Zhao C; Hu Z; Wei S; Huo Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 May; 27(5):343-8. PubMed ID: 26003637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat mesilate is not appropriate as an anticoagulant during continuous renal replacement therapy in dogs.
    Shimokawa Miyama T; Yoshioka C; Minami K; Okawa T; Hiraoka H; Itamoto K; Mizuno T; Okuda M
    J Vet Med Sci; 2010 Mar; 72(3):363-7. PubMed ID: 19959883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Circuit life span of continuous renal replacement therapy in critically ill patients with or without conventional anticoa-gulation: an observational prospective study].
    Sanz M; Hidalgo F; García-Fernández N
    An Sist Sanit Navar; 2017 Apr; 40(1):77-84. PubMed ID: 28534557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.